Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pexa-Vec + Nivolumab in Advanced HCC
NCT03071094Phase 2Terminated
- Sponsor
- Transgene SA
- Start
- Jul 2017
- Primary completion
- Sep 2020
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 2, open-label trial of pexastimogene devacirepvec in hepatocellular carcinoma (HCC) (2 arms), sponsored by Transgene SA. Primary endpoints: Dose Limiting Toxicities at 4 weeks, Serious Adverse Events at 4 weeks and 1 more. Started Jul 2017; status: terminated.
02
Drugs
pexastimogene devacirepvec
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03071094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03071094.